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Molecular basis of Streptococcus mutans sortase
A inhibition by the flavonoid natural product
trans-chalcone†
Daynea J. Wallock-Richards,‡a Jon Marles-Wright,‡b David J. Clarke,a
Amarnath Maitra,c Michael Dodds,c Bryan Hanleyd and Dominic J. Campopiano*a
Sortase A (SrtA) fromGram positive pathogens is an attractive target
for inhibitors due to its role in the attachment of surface proteins to the
cell wall. We found that the plant natural product trans-chalcone
inhibits Streptococcusmutans SrtA in vitro and also inhibited S. mutans
biofilm formation. Mass spectrometry revealed that the trans-chalcone
forms aMichael addition adduct with the active site cysteine. The X-ray
crystal structure of the SrtA H139A mutant provided new insights into
substrate recognition by the sortase family. Our study suggests that
chalcone flavonoids have potential as sortase-specific oral biofilm
inhibitors.
Sortases are a family of membrane-associated transpeptidases
which are highly conserved in Gram positive bacteria. They are
a promising target for inhibitors which have the potential to be
used as anti-infective therapies against pathogenic bacteria.1–3
Various sortase isoforms (SrtA, B, C) are responsible for covalently
attaching surface proteins involved in adherence to host cells,
iron acquisition, biofilm formation, invasion, signalling and pili
formation on the bacterial cell wall.2,4,5 Sortase A (SaSrtA) was
the first isoform of this family identified in Staphylococcus aureus
by Schneewind and colleagues, who also elucidated the catalytic
mechanism of the enzyme.6–10 The SrtA enzymes recognize a
conserved five amino acid sequence (LPXTG) at the C-terminus
of their protein substrates and cleave the amide bond between
the threonine and glycine residues using a highly-conserved
cysteine residue in the active site (Fig. S1, ESI†). The resulting
thioacyl intermediate is then attacked by the nucleophilic
pentaglycine side chain of lipid II, a cell wall precursor molecule,
to form a C-terminally linked surface protein.1,2
In addition to the conserved Cys residue in SrtA, two other
active site residues have been identified as essential for optimal
enzyme activity, a His side-chain which serves as a general base
and an Arg side-chain which stabilises the oxoanion intermediate
formed during the reaction.11–13 This catalytic triad (Cys–His–Arg) is
highly conserved among the sortase A enzymes (Fig. S2, ESI†).
Several classes of SrtA inhibitors have been identified and these
include compounds from small-molecule synthetic libraries,9,11,14,15
rationally designed peptidomimetics14,16 and natural products.17–20
Flavonoids21 are polyphenolic plant natural products and two in
particular, morin22 and curcumin,23,24 display good inhibition
against Streptococcus mutans SrtA. However, the exact molecular
basis of their activity has not been determined. Combining the
knowledge gained from these previous inhibitor studies we
hypothesized that trans-chalcone (Fig. 1A, inset), the precursor
molecule of many flavonoids, would inhibit the S. mutans SrtA
in vitro and possibly prevent bacterial biofilm growth.
The S. mutans SrtA enzyme was expressed in E. coli as an
N-terminal 40 amino acid truncation to remove the predicted
transmembrane domain (Fig. S3 and S4, ESI†) and the isolated
SrtA had a mass of 22 767 Da ([M + H]+, Fig. S5, ESI†) which
agrees well with the predicted value based on the sequence.25
The established FRET-based assay was used to measure the Km and
Vmax values (90.4  4.7 mM and 4.46  0.11  104 mM s1
respectively) for cleavage of the fluorogenic peptide substrate,
dabcyl-QALPETGEE-edans (Fig. S6, ESI†).26 Using the published
method,24 an IC50 value of 5  0.6 mM was determined for trans-
chalcone after incubating SrtA with varying concentrations of
inhibitor overnight (Fig. 1A and Fig. S7, ESI†). The rate of inhibition
was measured in a time dependent study by incubating 5 mM of the
enzyme with 100 mM of the inhibitor for various times (1, 2, 4, 8 and
16 h, Fig. 1B). Analysis of the enzyme activity revealed that the
inhibition of SrtA was slow, taking up to 16 h to reduce activity by
90%. Enzyme activity was not restored upon extensive dialysis of the
enzyme (not shown). Taken together these observations suggested
that trans-chalcone was a slow and tight binding inhibitor of SrtA.
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This led us to postulate that a covalent adduct was formed
between the inhibitor and the SrtA. To test this hypothesis, mass
spectrometry was used to analyse both the concentration and time
dependence of the reaction. From the mass spectrum we observed
a peak of 22767 Da for the mass of SrtA and an additional peak at
22975 Da (D208 Da) which corresponds to a single SrtA–chalcone
adduct (Fig. 1C). The formation of the adduct was also dependent
on the trans-chalcone concentration (Fig. 1D). Top-down fragmen-
tation mass spectrometry analysis confirmed the site of modifica-
tion on the enzyme to be Cys205, the only cysteine residue on SrtA
(Fig. S8, ESI†). Incubation of the inhibited enzyme with 10 mM
DTT overnight did not restore enzyme activity which suggested
an irreversible modification of the enzyme by trans-chalcone
(data not shown). Based on the mass increase and the site of
modification of SrtA by trans-chalcone, the proposedmechanism
for the reaction is via a Michael addition of trans-chalcone to
the free thiol of Cys205 (Fig. S9, ESI†). This proposition was
strengthened by analysing incubations of SrtA and dihydrochal-
cone (the saturated analogue of trans-chalcone) by enzyme assay
and mass spectrometry. This chalcone neither inhibited the
enzyme activity nor did we observe an additional SrtA peak of mass
increase of +210 Da (Fig. S10, ESI†). Taken together these data
highlight the requirement for the a,b-unsaturated system of trans-
chalcone and support our proposed Michael addition mechanism
rather than nucleophilic attack at the carbonyl carbon.
Inhibition of SrtA should lead to reduced attachment of various
cell surface proteins that eﬀect biofilm formation so, with strong
evidence that chalcone modifies SrtA in vitro, we tested the natural
product using a S. mutans biofilm assay. The cells were assayed for
growth on saliva-coated glass slides using the acta active adhesion
(AAA) model by measuring quantitatively the biofilm biomass after
16–18 h of growth (Fig. S11, ESI†).27 The S. mutans cells were grown
in different concentrations of trans-chalcone (0–500 mM) and the
resulting biofilm biomass was measured. Morin, a known biofilm
disruptor, was used as a positive control. We observed that biofilm
formation was reduced in the presence of trans-chalcone in a
concentration dependent manner up to 250 mM, with efficacy tailing
off at higher concentrations (Fig. S11, ESI†). Since biofilm formation
is a complex and dynamic process that involves changes inmicrobial
metabolism and signaling, this encouraging result suggests that the
exact mechanism of chalcone inhibition in vivo requires further in-
depth study.22
We attempted to gain structural insight into the SrtA:inhibitor
interaction but we noticed that the wild-type SrtA enzyme was
unstable during crystal trials due to auto-proteolysis (Fig. S12A,
ESI†). To overcome this we produced and crystallised the more
stable SrtA H139A mutant (Fig. S12B, ESI†) and, as expected,
although this mutant was inactive in the in vitro fluorescent assay,
we still observed the formation of the trans-chalcone adduct upon
incubation of the SrtA H139A mutant enzyme with the inhibitor
(Fig. S13, ESI†). This suggests that the mutant undergoes a similar
Michael addition to the wild-type SrtA. Crystals of the SrtA H139A
mutant defracted to 1.6 Å (Fig. S14, ESI†) and the crystal structure
(PDB code: 4TQX) was determined by molecular replacement using
the structure of the S. pyogenes SrtA as the starting model (PDB
code: 3FN5).13 The electron density map at residues 49–53 at
the N-terminus was ambiguous and suggests some degree of
flexibility in this region; therefore these residues were omitted
from the final model. The S. mutans SrtA has a canonical eight
stranded b-barrel core (Fig. 2A, Fig. S15A, ESI†) which is highly
conserved among the sortase superfamily.12
Our construct lacks the predicted N-terminal forty amino acids of
the trans-membrane domain but the structure revealed a unique,
extended N-terminal helix (residues 69–89, relative to the full-length
enzyme) which is absent from all other sortase A structures present
in the PDB (Fig. S15B, ESI†). This helix is extended away from the
catalytic domain but connected to it by a short loop (residues 89–93).
An N-terminal helix was observed in the crystal structure of S. aureus
SrtB (PDB: 1NG5).28 However, in contrast to our structure, this helix
is hinged at Asp41 in SrtB and places it in an equivalent position to
the C-terminus of SrtA (Fig. S15A, ESI†). This is the first observation
of the SrtA N-terminal domain and its structure suggests that it plays
an important functional role in positioning the catalytic domain of
sortases above the membrane where it can efficiently interact with it
substrates.
The relative positions of the active site residues of SrtA (Cys205,
Arg213) are highly conserved across the family, with no architectural
compromises evident by introduction of the H139A mutation
(Fig. S15C, ESI†). The only significant diﬀerence is observed between
the cysteine residue of S. aureus SrtB (SaSrtB) and the other sortase
enzymes. In SaSrtB, the cysteine residue points towards the histidine
residue in the active site, whereas in the other sortases the cysteine
residue points away from theHis separated by a distance ofB7 Å. In
the crystal structure of the SrtA H139A mutant, Cys205, Ala139 and
Arg213 are positioned on three neighboring b-strands, b-7, b-4 and
b-8 respectively which forma tunnel-like hydrophobic pocket, similar
to that described in other SrtA enzymes which are thought to adopt a
conformation that is ideal for receiving the natural peptide substrate.
Interestingly, when viewing the unit cell, the N-terminal a-helix
(residues 69–89) from a symmetry-related molecule, makes extensive
Fig. 1 (A) Inhibition of SrtA by trans-chalcone (inset) after incubation with
varying concentrations of the inhibitor. The IC50 of trans-chalcone is 5 
0.6 mM. (B) Inhibition of SrtA by 100 mM trans-chalcone over time (1, 2, 4, 8
and 16 h) (C) incubation of 5 mM SrtA (22 767 Da) with 100 mM trans-
chalcone leads to a time-dependent formation of a SrtA–chalcone adduct
(22 975 Da, Dmass 208 Da). (D) Modification of 5 mM SrtA with trans-
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contacts with the active site cleft/binding groove of SrtA (Fig. 2A).
These serendipitidous ‘‘non-physiological dimers’’ involving the
active site offer a structural rationale as to why the wild type SrtA
undergoes auto-proteolysis. Although it does not contain a canonical
‘‘sortase motif’’ it appears that the N-terminus of SrtA binds to the
active site and this self-recognition leads to amide bond cleavage.
Although we prepared milligram quantities of chalcone-modified
SrtA H139A it was diﬃcult to handle at high concentrations and
failed to crystallise. Recently, Schneewind and colleagues were able
to identify a new class ofmechanism-based inhibitors, aryl(b-amino)-
ethyl ketones (AAEK) from a screen of over 135000 compounds
which irreversibly modify the active site cysteine residue of SrtA and
SrtB.15 Therefore, guided by the SaSrtA:LPETG peptide complex
structure (PDB 1T2W),10 the B. anthracis SrtB-modified with aryl-
(b-amino)ethyl ketone (SrtB–AAEK, PDB: 2OQZ),15 and the positions
of the bound Phe67 and Phe69 side-chains from the symmetry-
related partner in our SrtA structure, we were able to construct
models of the SrtA–chalcone bound adduct. We used the phenyl
rings of both amino acids from the symmetry-related partner to
place the two aromatic rings of the inhibitor covalently-bound to the
thiol of Cys205. Interestingly, there is space to accommodate the
adduct in the active site cleft in either the R- or the S-configuration
(Fig. 2C). Of course there is free rotation about the C–S bond that
could potentially swap the position of the rings. That said, by
comparing the structure of the SrtB–AAEK adduct with our SrtA–
chalcone adduct model, we note that the SrtA active site is open at
both ends, in contrast to the SrtB-binding cleft which is blocked by
Tyr235. These structural differences suggest a possible strategy for
exploiting more structurally diverse chalcones drawn from the
flavonoid family as isoform-specific sortase inhibitors.
In summary, our study provides strong evidence that trans-
chalcone inhibits S. mutans SrtA by covalently modifying its
target and also reveals novel aspects of the structure and
mechanism of the sortase family. Biofilm inhibition data also
lends support for further eﬀorts into potential uses of natural
products to control the growth of oral flora.
This work was supported by Wm. Wrigley Jr. Company (DJW-R)
and the University of Edinburgh (DJW-R, JM-W, D. J. Clarke).
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Fig. 2 Crystal structure of S. mutans SrtA H139A. (A) Surface representation
of one molecule, colored by charge, with a symmetry related SrtA shown as
a cartoon (grey). The N-terminal region of the symmetry-related SrtA makes
extensive contacts and the extended helix occludes the active site cleft.
(B) Experimental 2mFo-DFc map contoured at 1.5s showing residues
(Phe67/69) of the N-terminal helix within the active site cleft. (C) Model of
the Michael adduct of trans-chalcone bound to Cys205 of SrtA in both
possible configurations. The pink model shows the A-aryl ring of the R-form
of the adduct bound in the LPXTG binding site and the B-aryl ring in the
proposed lipid II binding site. The blue model shows the S-form of the adduct
with the B-aryl ring in the LPTXG pocket and the A-aryl ring in the lipid II site.
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